drugset

drugset / Trial / NCT07033585

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

NCT07033585 ↗

Phase 2/3 Active not recruiting 600 enrolled Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair UnitedHealthcare · collab

RandomizedParallel-groupQuadruple-blindHealth-services research

Summary

Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers

Timeline

Start: 2025-06-15
Primary completion: 2026-10-18
Completion: 2026-11-28

Publications

Results Xu Y, Wu P, Wen W, Chen H. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety]. Nan Fang Yi Ke Da Xue Xue Bao. 2019 Nov 30;39(11):1305-1311. doi: 10.12122/j.issn.1673-4254.2019.11.07. Chinese.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dapagliflozin	Small molecule	10 mg	Oral
Subject	Metformin	Small molecule	500 mg	Oral
Subject	SAXAGLIPTIN ANHYDROUS	Small molecule	5 mg	Oral

Indications